Investor Presentation - First Six Months of 2021

27 Investor presentation First six months of 2021 Insulin sales remain important with more than 40% share of revenue but with less dependence on the US insulin sales 45% Q2 2016 sales split IO: International Operations; NAO: North American Operations 25% 30% Q2 2021 sales split 30% 58% 11% IO insulin NAO insulin Other products Novo NordiskⓇ

View entire presentation